%PDF-1.4
%
103 0 obj
<>
endobj
100 0 obj
<>
endobj
244 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-11-29T12:37:22Z
2024-03-28T22:20:20-07:00
QuarkXPressª: AdobePS 8.6 (219)
2024-03-28T22:20:20-07:00
application/pdf
Heather
201188.aug
uuid:74af8493-1dd2-11b2-0a00-0509271d5700
uuid:74af8495-1dd2-11b2-0a00-bf0000000000
endstream
endobj
89 0 obj
<>
endobj
90 0 obj
<>
endobj
104 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
4 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
17 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
30 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
58 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
71 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
79 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
82 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
286 0 obj
[291 0 R]
endobj
287 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.06 612 -792 re
W n
BT
/CS0 cs 0 0 0 1 scn
/GS1 gs
/TT0 1 Tf
-0.00011 Tc 8 0 0 8 72 714.5293 Tm
(interferon-)Tj
/T1_0 1 Tf
0 Tc [0.4 (\003)]TJ
/TT0 1 Tf
0.02499 Tw 4.9603 0 Td
(to inhibit osteoclast formation. J Exp Med)Tj
0 Tw -4.9603 -1.25 Td
(1997;185:1005-12.)Tj
-0.00011 Tc 0.02499 Tw -1.875 -1.25 Td
[(20.)-625 (Dao )18 (T)74 (, Ohashi K, Kayano )18 (T)74 (, Kurimoto M, Okamura H. Interferon-)]TJ
/T1_0 1 Tf
0 Tc 0 Tw 28.7915 0 Td
(\003)Tj
/TT0 1 Tf
[0.1 (-)]TJ
0.02499 Tw -26.9165 -1.25 Td
[(inducing factor)40 (, a novel cytokine, enhances Fas ligand-mediated)]TJ
0 -1.25 TD
[(cytotoxicity of murine )18 (T)-257 (helper 1 cells. Cell Immunol)]TJ
0 Tw T*
(1996;173:230-5.)Tj
-0.00011 Tc 0.02499 Tw -1.875 -1.25 Td
[(21.)-625 (Gracie JA, Forsey RJ, Chan )18 (WL, et al. )55 (A)-220 (proinflammatory role for)]TJ
0 Tc 1.875 -1.25 Td
(IL-18 in rheumatoid arthritis. J Clin Invest 1999;104:1393-401.)Tj
-0.00011 Tc -1.875 -1.25 Td
[(22.)-625 (Leung BP)111 (, McInnes IB, Esfadiari E, )18 (W)80 (ei XQ, Liew FY)129 (. Combined)]TJ
0 Tc 1.875 -1.25 Td
[(ef)18 (fects of IL-12 and IL-18 on the induction of collagen-induced)]TJ
T*
(arthritis. J Immunol 2000;164:6495-502.)Tj
-0.00011 Tc -1.875 -1.25 Td
[(23.)-625 (Arnett FC, Edworthy SM, Bloch DA, et al. )18 (The )55 (American)]TJ
1.875 -1.25 Td
[(Rheumatism )55 (Association 1987 revised criteria for classification of)]TJ
0 Tc T*
[(rheumatoid arthritis. )55 (Arthritis Rheum 1988;31:315-24.)]TJ
-1.875 -1.25 Td
[(24.)-625 (Altman RD, )55 (Asch E, Bloch D, et al. Development of criteria for the)]TJ
-0.00011 Tc 1.875 -1.25 Td
(classification and reporting of osteoarthritis. Classfication of)Tj
0 Tc T*
[(osteoarthritis of the knee. )55 (Arthritis Rheum 1986;29:1039-49.)]TJ
-0.00011 Tc -1.875 -1.25 Td
[(25.)-625 (Asselin S, Conjeaud H, Minty )55 (A, Fradelizi D, Breban M. Stable)]TJ
0 Tc 1.875 -1.25 Td
[(polarization of peripheral blood )18 (T)-257 (cells towards type 1 or type 2)]TJ
T*
(phenotype after polyclonal activation. Eur J Immunol 1998;)Tj
0 Tw T*
(28:532-9.)Tj
-0.00011 Tc 0.02499 Tw -1.875 -1.25 Td
[(26.)-625 (T)70 (one M, )18 (Thompson SAJ, )18 (T)70 (one )37 (Y)129 (, Fairchild PJ, )18 (W)80 (aldmann H.)]TJ
1.875 -1.25 Td
(Regulation of IL-18 \(IFN-)Tj
/T1_0 1 Tf
0 Tc 0 Tw [-0.1 (\003)]TJ
/TT0 1 Tf
0.02499 Tw 11.2843 0 Td
(inducing factor\) gene expression. )Tj
-11.2843 -1.25 Td
(J Immunol 1997;159:6156-63.)Tj
-0.00011 Tc 31.125 28.75 Td
[(27.)-625 (Puren )55 (AJ, Fantuzzi G, Dinarello CA. Gene expression, synthesis,)]TJ
0 Tc 1.875 -1.25 Td
(and secretion of interleukin 18 and interleukin 1 beta are)Tj
T*
[(dif)18 (ferentially regulated in human blood mononuclear cells and)]TJ
T*
[(mouse spleen cells. Proc Natl )55 (Acad Sci USA)-220 (1999;96:2256-61.)]TJ
-1.875 -1.25 Td
[(28.)-625 (Olee )18 (T)74 (, Hashimoto S, Quach J, Lotz M. IL-18 is produced by)]TJ
1.875 -1.25 Td
(articular chondrocytes and induces proinflammatory and catabolic)Tj
T*
(responses. J Immunol 1999;162:1096-100.)Tj
-0.00011 Tc -1.875 -1.25 Td
[(29.)-625 (Kobayashi )37 (Y)129 (, Ichijo )37 (Y)129 (, Nagatake H, )18 (W)80 (atanabe N, Nishizawa K,)]TJ
1.875 -1.25 Td
(Goto M. Processing of interleukin-1 beta in synovial cells freshly)Tj
0 Tc T*
(isolated from patients with rheumatoid arthritis. Biochem Biophys)Tj
T*
(Res Commun 1994;199:1035-40.)Tj
-0.00011 Tc -1.875 -1.25 Td
[(30.)-625 (Fantuzzi G, Reed DA, Dinarello CA. IL-12-induced IFN-)]TJ
/T1_0 1 Tf
0 Tc 0 Tw 25.0964 0 Td
(\003)Tj
/TT0 1 Tf
-0.0002 Tc 0.6859 0 Td
(is)Tj
-0.00011 Tc 0.02499 Tw -23.9073 -1.25 Td
[(dependent on caspase-1 processing of the IL-18 precursor)55 (. J Clin)]TJ
0 Tc T*
(Invest 1999;104:761-7.)Tj
-1.875 -1.25 Td
[(31.)-625 (Morita )37 (Y)129 (, )37 (Y)100 (amamura M, Nishida K, et al. Expression of interleukin-)]TJ
1.875 -1.25 Td
(12 in synovial tissue from patients with rheumatoid arthritis.)Tj
T*
(Arthritis Rheum 1998;41:306-14.)Tj
-1.875 -1.25 Td
[(32.)-625 (Ahn HJ, Maruo S, )18 (T)70 (omura M, et al. )55 (A)-220 (mechanism underlying)]TJ
-0.00011 Tc 1.875 -1.25 Td
[(syner)18 (gy between IL-12 and IFN-)]TJ
/T1_0 1 Tf
0 Tc 0 Tw 13.2426 0 Td
(\003)Tj
/TT0 1 Tf
0.02499 Tw [0.1 (-inducing factor in enhanced)]TJ
-0.00011 Tc -13.2426 -1.25 Td
(production of IFN-)Tj
/T1_0 1 Tf
0 Tc 0 Tw [-0.3 (\003)]TJ
/TT0 1 Tf
0.02499 Tw [0.1 (. J Immunol 1997;159:2125-31.)]TJ
-1.875 -1.25 Td
[(33.)-625 (Y)100 (oshimoto )18 (T)74 (, )18 (T)70 (akeda K, )18 (T)70 (anaka )18 (T)74 (, et al. IL-12 upregulates IL-18)]TJ
1.875 -1.25 Td
[(receptor expression on )18 (T)-257 (cells, )18 (Th1 cells and B cells: Syner)18 (gy with)]TJ
-0.0002 Tc T*
(IL-18 for IFN-)Tj
/T1_0 1 Tf
0 Tc 0 Tw 5.9353 0 Td
(\003)Tj
/TT0 1 Tf
0.02499 Tw 0.6859 0 Td
(production. J Immunol 1998;161:3400-7.)Tj
ET
/CS0 CS 0 0 0 1 SCN
54 54 m
558 54 l
S
BT
/TT1 1 Tf
8 0 0 8 54.5 35.9844 Tm
[(T)92 (anaka, et al: Matur)37 (e IL-18 in RA)]TJ
0 Tw 60.9375 -0.0313 Td
(1787)Tj
ET
0 0 0 0 scn
/GS0 gs
101.68 57.14 407.5 -10.83 re
f*
0.5 w
101.68 57.14 407.5 -10.83 re
S
Q
Q
q
1 0 0 1 0 -1 cm
0 0 612 792 re
W n
1 0 0 1 0 1 cm
BT
0 g
ET
/GS2 gs
BT
/T1_1 8 Tf
120.092 50 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2001. All rights reserved.)Tj
ET
Q
BT
0 g
/GS3 gs
/T1_2 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS3 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS3 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
111 0 obj
<>
endobj
147 0 obj
<>
endobj
250 0 obj
<>
endobj
117 0 obj
<>
endobj
108 0 obj
<>
endobj
107 0 obj
<>
endobj
137 0 obj
<>stream
HVpg~s""4.A\$nBs" Rde2mbuۆ6֎Ŭbۚi'A3;{Vk-#=2[;F6#WL"7{N1/'څ88Kn#ÁHDO/ܱG|kwuF&<("EX
dv 4Y4Z^sWܟBK<'&HjY;$tldܩzmb_\b&
r8$NKVV((u̳&`0yOtyxwD!2E"sBΑ7RXCL$;d%P(d^C:2{p =EH~_2RHC4e2G=^ѼwVUl͵>ax]ɘFe̽^c)Jm7l'?q
y
$]]:NqxPY箼ϩ3gFD(S41]TJ1W.1UMfEq]w^MFNRL,TEr|K#76Gi=(*H%YUF)c2WW*۔ߕJ@yjAUX)Ro':E=0dÚmc {P
~Y#f6^+X-|߁}L؊Ac-H. bx;{xi8G@}TC[vaq>Y=)gԮkD/>z^?8с\b:}g GxA.C^-˝DzA} yۛUɽ3F֢ AO@a3Xf9r?GT(Pn4< P)"_4
>2@ɀk L]aG3T6XU f`RI@JT@R *y
E%U`P+ zU@N Jv*Qv d RI1FzF*Khzm\l6opUWqm"ҷi<"]HW"3ʶiAlziV\.Lu쨓I>UuNʭT|K6wK_vKyRN
'Ϥק#Y8ՃϢ\0K?)cXBGp\S ѳRp%e ˢ -J9]qZmƍ]>O .u{~f%6jTiU0R,j g$ݘ0t F=wTGWS8~^/5As^@azOyxwҟvz ^BoӕUuq&>"(r .Q**De,R.*-*YMoћiTQ|8 @'0-0p XOP]"=5. ;@:@Az_fGH/"7_zhXc"Kp
#(c$83/y~xf,Vg3 RŠtBݙeo АqD
9i4b0mi.m?spqJp JR8/I)Pj<2'g<67%̅ s!7=6{ڄߚa^\@Y`Ebnrb5";X3.G[4 A !Յ|eF:1=фB!67"~d3&+P4 UP%9fbQjX٣],hlRX)V1xHEi46ź0:>+)ƭX'd1,YQ&P^[?؎V7paUOFB0ON5X
bM1RCA>G>fѭso)Oݒa vGʖWΚTފM5cҨ\9~6Ӗ{WOcwChe ic_eCxlBiHɹS+'"$ळ
Ϟeϰұ(B\|?KUyF5fL/ck
#Ab